Attached files
| file | filename |
|---|---|
| EX-10.1 - EX-10.1 - Tracon Pharmaceuticals, Inc. | tcon-ex101_102.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 10, 2020
|
TRACON Pharmaceuticals, Inc. |
||
|
(Exact name of registrant as specified in its charter) |
||
|
|
|
|
|
Delaware |
001-36818 |
34-2037594 |
|
(State or other jurisdiction |
(Commission File Number) |
(IRS Employer Identification No.) |
|
of incorporation) |
|
|
|
|
|
|
|
4350 La Jolla Village Drive, Suite 800 San Diego, California |
|
|
|
(Address of principal executive offices) |
(Zip Code) |
|
|
|
||
|
Registrant’s telephone number, including area code: (858) 550-0780 _______________________________________________________________________________________ |
||
|
|
||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Securities Act:
|
Title of each class |
Trading symbol(s) |
Name of each exchange on which registered |
|
Common Stock, par value $0.001 per share |
TCON |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
The disclosure set forth under Item 2.03 of this Current Report on Form 8-K is incorporated into this Item 1.01 by reference.
|
Item 2.03 |
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. |
On April 10, 2020, TRACON Pharmaceuticals, Inc. (the “Company”) entered into a deferral agreement related to its amended and restated loan and security agreement with Silicon Valley Bank (“SVB”). The deferral agreement defers the Company’s obligations to make principal payments for six months, with interest only payments until November 1, 2020. In connection with the deferral of principal payments, the deferral agreement extends the maturity date of the amended and restated loan and security agreement by six months to June 2022.
The foregoing is only a brief description of the deferral agreement, does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to the deferral agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K.
|
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit No. |
Description |
|
10.1 |
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
TRACON Pharmaceuticals, Inc. |
||
|
|
|
|
||
|
Dated: April 15, 2020 |
|
|
||
|
|
|
By: |
/s/ Charles P. Theuer, M.D., Ph.D. |
|
|
|
|
|
Charles P. Theuer, M.D., Ph.D. |
|
|
|
|
|
President and Chief Executive Officer |
|